Fundraising Fox
/People
Sign in

David Mott

Former General Partner at New Enterprise Associates (NEA)

Montana

Writes $100K – $10M checks · typically $1M

Find your path to David

Sign up to find every way you can get introduced to David

  • Your email: the people you already email who know David
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with David
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

About

David Mott is an investor at Sphinx Mountain Capital and chairman of Novavax, with more than 30 years of experience in the biopharmaceutical industry. His investment work spans venture, growth and public equity, real estate, fixed income and private equity, along with family office management, estate and generational wealth planning, and tax strategy. He has participated in over $40 billion in fundraising, acquisitions and capital formation, more than 35 IPOs, the development and commercialization of over a dozen drugs and vaccines, and service on more than 30 for-profit and not-for-profit boards.

Experience

  1. NovavaxChairmancurrent2026 — presentGaithersburg, MD
  2. NovavaxBoard Member2020 — 2026Gaithersburg, MD
  3. American RiversBoard Membercurrent2025 — presentWashington, DC
  4. Sphinx Mountain Capital LLCChief Executive Officer and Chief Investment Officercurrent2025 — presentBig Sky, MT
  5. Big Sky Youth EmpowermentBoard Membercurrent2024 — present
  6. Mott Family FoundationChief Executive Officercurrent2024 — presentBig Sky, MT
  7. Ardelyx, Inc.Chairmancurrent2008 — presentWaltham, Massachusetts, United States
  8. Yellowstone Club Community FoundationBoard Member2024 — 2026
  9. Mersana TherapeuticsChairman2013 — 2026Cambridge, Massachusetts, United States
  10. AdaptimmuneChairman2014 — 2025Greater Oxford Area
  11. Mott Family CapitalPrivate Investor2020 — 2025Big Sky, Montana, United States
  12. Imara, IncChairman2016 — 2023Cambridge, MA
  13. EpizymeChairman2009 — 2022Cambridge, MA
  14. Polyneuron Pharmaceuticals AGBoard Member2019 — 2020Basel, Basel-Town, Switzerland
  15. Tiburio TherapeuticsBoard Member2019 — 2020Cambridge, Massachusetts, United States
  16. Cydan Development, Inc.Chairman2013 — 2020Cambridge, MA
  17. New Enterprise Associates (NEA)General Partner2008 — 2020Chevy Chase, MD
  18. 3-V BiosciencesChairman2008 — 2020Menlo Park, CA
  19. NightstaRx LimitedBoard Member2015 — 2019London, United Kingdom
  20. TESARO, Inc.Chairman2010 — 2019Waltham, MA
  21. XTuit Pharmaceuticals, Inc.Board Member2015 — 2018Walhtam, MA
  22. Clementia PharmaceuticalsBoard Member2015 — 2018Montreal, Quebec, Canada
  23. Vtesse, Inc.Chairman2015 — 2017Gaithersburg, MD
  24. Edimer PharmaceuticalsBoard Member2013 — 2016Cambridge, MA
  25. ProsensaChairman2012 — 2014Leiden, Netherlands
  26. Zyngenia, IncChairman2009 — 2014Gaithersburg, MD
  27. St. Albans School (D.C.)Member Board of Trustees2008 — 2014Washington, DC
  28. Omthera Pharmaceuticals, Inc.Board Member2011 — 2013Princeton, NJ
  29. MedImmunePresident & Chief Executive Officer, Vice Chairman2000 — 2008Gaithersburg, MD
  30. MedImmuneVarious Positions: President, Chief Operating Officer, Chief Financial Officer, EVP, VP, etc...1992 — 2000Gaithersburg, MD
  31. ShireBoard Member2007 — 2008Dublin, Ireland
  32. RibX PharmaceuticalsBoard Member2006 — 2008New Haven, CT
  33. Ambit PharmaceuticalsBoard Member2004 — 2007San Diego, CA
  34. Beauvoir Elementary SchoolMember of the Board of Trustees2001 — 2007Washington, DC
  35. ConceptisChairman1999 — 2003Montreal, Canada Area
  36. Saint James SchoolMember of the Board of Trustees1997 — 2003
  37. Smith Barney, Harris Upham & Co.Various Positions: Vice President, Associate, Analyst1986 — 1992New York, NY

Network4

Beth Seidenberg
Founding Managing Director at Westlake Village BioPartners
Peter Erin
Investor at Riverfront Ventures, LLC
Sara Nayeem
Partner at Avoro Capital Advisors
Ven Raju
President & CEO at Ben Franklin Technology Partners

Investors connected to David in public investor directories — a warm-intro map.

Frequently asked questions

Who is David Mott?
David Mott is an investor at Sphinx Mountain Capital and chairman of Novavax, with more than 30 years of experience in the biopharmaceutical industry. His investment work spans venture, growth and public equity, real estate, fixed income and private equity, along with family office management, estate and generational wealth planning, and tax strategy. He has participated in over $40 billion in fundraising, acquisitions and capital formation, more than 35 IPOs, the development and commercialization of over a dozen drugs and vaccines, and service on more than 30 for-profit and not-for-profit boards.
What check size does David Mott write?
David Mott typically writes checks of $100K – $10M.
Where did David Mott go to school?
David Mott studied at Dartmouth College (Bachelor’s Degree, Economics and Government); Saint James School (High School).

Same school

Shared employers